🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 22 of 857 · Phase 3 first, then by program name

  1. Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)

    phase 3 small molecule active

    1 trial

  2. Atogepant, Placebo for Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  3. Atogepant, Placebo for Atogepant

    AbbVie Deutschland GmbH & Co. KG

    Menstrual Migraine

    phase 3 small molecule active

    1 trial

  4. Atogepant, Placebo for atogepant tablets 60mg

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 3 small molecule active

    1 trial

  5. Atomoxetine Aurobindo 40 mg hard capsules, Microcrystalline cellulose gelatin capsule

    Disc Medicine

    Parkinson's disease

    phase 3 small molecule active

    1 trial

  6. Atorvastatin

    Amgen

    Hyperlipidemia

    phase 3 small molecule completed

    1 trial

  7. Atorvastatin

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  8. Atropine Eye Drops, Solution (0.05% w/v), Atropine Eye Drops, Solution (0.025% w/v), The placebo consists of the same composition as the atropine eye drops except for the active substance.

    Elan Pharma International

    Myopia

    phase 3 small molecule active

    1 trial

  9. Atropine sulfate eye drops 0.01%

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myopia

    phase 3 small molecule active

    1 trial

  10. Attentin 10 mg Tablette, Dexamfetamine sulfate 20 mg modified-release capsule, Placebo for Test 1 - 5 mg, Attentin 5 mg, Tablette, Placebo for test 2 - 10 mg, Placebo for test 1 - 10 mg, Placebo for test 2 - 20 mg, Dexamfetamine sulfate 15 mg modified-release capsule, Placebo for test 2 - 15 mg, Dexamfetamine sulfate 10 mg modified-release capsule

    Medice Arzneimittel Pütter GmbH & Co. KG

    Patients with ADHD (according to ICD-10 / DSM-5)

    phase 3 small molecule active

    1 trial

  11. Atumelnant

    Crinetics Pharmaceuticals Europe GmbH

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    2 trials

  12. Atumelnant 120 mg tablets, Atumelnant 80 mg tablets, Tablet

    Lacuna Pharma Pty Ltd

    Classic Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    1 trial

  13. Atumelnant 80 mg tablets, Atumelnant 40 mg tablet, Atumelnant 20 mg tablets, Tablet

    Lacuna Pharma Pty Ltd

    Classic congenital adrenal hyperplasia

    phase 3 small molecule active

    1 trial

  14. Augmentin Fruit, 400 mg/57 mg/5 ml suukaudse suspensiooni pulber

    Istituto Gentili S.r.l.

    Urinary Tract Infections

    phase 3 small molecule active

    1 trial

  15. Auto-CD34+ cells

    LISATA THERAPEUTICS, INC.

    Chronic Myocardial Ischemia

    phase 3 mab completed

    1 trial

  16. Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)

    LISATA THERAPEUTICS, INC.

    Stage IV Melanoma

    phase 3 mab terminated

    1 trial

  17. Autologous Peripheral Blood Stem Cell injection

    Hospital Authority, Hong Kong

    Acute Myocardial Infarction

    phase 3 mab active

    1 trial

  18. Avacincaptad pegol, FLUORESCEIN

    Astellas Pharma GmbH

    geographic atrophy

    phase 3 small molecule active

    1 trial

  19. Avastin 25 mg/ml concentrate for solution for infusion., Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  20. Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM LEVOFOLINATE , MK-1084, CETUXIMAB , MVASI 25 mg/mL concentrate for solution for infusion, FLUOROURACIL , Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM FOLINATE , OXALIPLATIN , MK-1084, MVASI 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  21. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    intermediate-stage hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  22. Avelumab

    Pfizer

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

  23. Avelumab

    Serono Europe Limited

    First Line Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  24. Avexitide

    Amylyx Pharmaceuticals EMEA B.V.

    Post Bariatric Hypoglycemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources